$SRPT News

Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price Target

Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs

Sarepta Therapeutics Says FDA Accept sNDAs For AMONDYS 45 And VYONDYS 53 For Treatment Of Duchenne Muscular Dystrophy; PDUFA Target Action Data February 28, 2027

Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Sarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call Transcript

A Look At Sarepta Therapeutics (SRPT) Valuation After Q1 Profitability Return And Pipeline Progress

Sarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush Says

Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?

Sarepta tumbles as its gene therapy sales decline further

Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained

Sarepta Stock Slumps. Why an Earnings Beat Wasn’t Enough for the S&P 500 Loser.

Sarepta Therapeutics Q1 Earnings Call Highlights

Sarepta Therapeutics, Inc. Q1 2026 Earnings Call Summary

Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript

Sarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to Say

Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates

Sarepta Therapeutics (NASDAQ:SRPT) Q1 2026 Earnings Beat Overshadowed by Revenue Dip

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

Sarepta Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation